Clinical trials: Essential Hypertension.
Essential Hypertension
To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil
The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/sustained-release indapamide (240 mg/1.5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week…
- Trial name
- NCT06500689
- Testing
- Allisartan Isoproxil/Sustained-Release Indapamide, Allisartan Isoproxil
- Where
- 40 sites in China
- Volunteers
- 366 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Essential Hypertension
Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients
Hypertensive patients with moderate hypertension have a risk to develop cardiovascular events of 15-20% over a period of 10 years.
- Trial name
- NCT00716950
- Testing
- valsartan/amlodpine, losartan/amlodpine
- Where
- Italy
- Volunteers
- 187 people
- Sponsor
- University of Pavia
Hypertension, Hypertension,Essential
Effects of Electrical Nervous Stimulation Transcutaneous in Hypertensive Patients
Systemic arterial hypertension is a disease characterized by high blood pressure levels. It has a high prevalence, is a precursor of cardiovascular diseases, resulting in high costs to the health system and increased mortality.
- Trial name
- NCT06025643
- Testing
- TENS - Cervical stimulation group, TENS - Plus cervical stimulation group, TENS - Renal stimulation group
- Volunteers
- 40 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Essential Hypertension, Primary Hypercholesterolemia
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or…
- Trial name
- NCT07685054
- Volunteers
- 12,700 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
- Trial name
- NCT06643819
- Testing
- Sacubitril∙Valsartan(dose maintenance), Sacubitril∙Valsartan(dose increasing), Valsartan
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and tolerability of 8 week treatment with Fimasartan (BR-A-657-K) 20, 60, 120, 240 mg and placebo in patients with mild to moderate essential hypertension and…
- Trial name
- NCT00923611
- Testing
- Fimasartan
- Where
- South Korea
- Volunteers
- 182 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension
The aim of this observational study is to monitor the effectiveness of therapy, adherence and safety of a fixed combination of perindopril + amlodipine in patients with essential hypertension.
- Trial name
- NCT07876895
- Testing
- fixed combination of perindopril + amlodipine
- Where
- Bosnia and Herzegovina
- Volunteers
- 600 people
- Sponsor
- Bosnalijek D.D
Heart Failure, Essential Hypertension
LCZ696 in Advanced LV Hypertrophy and HFpEF
Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and will be treated for 24 weeks.
- Trial name
- NCT03928158
- Testing
- LCZ 696, Valsartan
- Where
- Russia
- Volunteers
- 61 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Primary Hypertension
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
- Trial name
- NCT06884085
- Testing
- Co-administration of AD-227A and AD-227B, Administration of AD-227
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
Essential Hypertension
Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study
Background: The use of thiazide diuretics in the treatment of hypertension (HT) is widely considered a first line treatment, given the efficacy and low cost of this class of drugs.
- Trial name
- stayondiur (NCT00408512)
- Testing
- thiazides, Non thiazidic treatment
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- Federico II University
Hypertension
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
- Trial name
- NCT00624065
- Testing
- carvedilol controlled release/lisinopril
- Where
- 76 sites in United States
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Hypertension
SPP100 Dose Finding Study in Japan
This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.
- Trial name
- NCT00311012
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 445 people
- Sponsor
- Novartis
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetics and the safety after administration of BR1018 and coadministration of BR1018A and BR1018B in healthy volunteers
- Trial name
- NCT06889012
- Testing
- BR1018, BR1018A, BR1018B
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Essential Hypertension
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy
- Trial name
- NCT06682000
- Testing
- DWC202404, DWC202314, DWC202404, DWC202314P
- Where
- South Korea
- Volunteers
- 192 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Primary Hypertension, Obesity
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.
Despite the available means of treating primary arterial hypertension, the prevalence of hypertensive patients with inadequately controlled blood pressure levels, remains high.
- Trial name
- NCT06208072
- Testing
- Irbesartan 150mg, Eplerenone 25 mg
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Hippocration General Hospital
Lower Leg Edema, Orthostatic Hypertension
Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Essential Hypertension Patients
Levacalm Tab. was approved in Jul 2013 by MFDS in South Korea. Levacalm Tab. is combination drug of Valsartan as an angiotensin II receptor blocker and Lercanidipine as a Calcium channel blocker.
- Trial name
- NCT02415192
- Testing
- Levacalm, Valsartan/amlodipine
- Where
- South Korea
- Volunteers
- 2,001 people
- Sponsor
- LG Life Sciences
Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02483936
- Testing
- Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg, Olmesartan 40mg + Hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Essential Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02493322
- Testing
- Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg, Olmesartan medoxomil 20mg + Chlortalidone 25mg, Olmesartan 20mg + hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Prevention, Arterial Hypertension
Possibilities of Perceiving Information on the Primary Prevention of Cardiovascular Diseases in Persons Suffering From Essential Hypertension Through a Social Network
A randomized, prospective study conducted on the basis of a social network (Instagram platform), two-stage. At the first stage, the online school "Save Your Heart" was announced and 945 applicants were enrolled in the training.
- Trial name
- SocialCor (NCT04944472)
- Testing
- HDKQ questionnaire
- Where
- Russia
- Volunteers
- 125 people
- Sponsor
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department